Volume 15, Issue 2 (3-2017)                   IJRM 2017, 15(2): 87-92 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Ghasemi N, Dehghani Firouzabadi R, Ahmadi S. Association of -460C/T and +405 G/C polymorphisms of vascular endothelial growth factor gene and susceptibility of ovarian hyperstimulation syndrome. IJRM 2017; 15 (2) :87-92
URL: http://ijrm.ir/article-1-802-en.html
Association of -460C/T and +405 G/C polymorphisms of vascular endothelial growth factor gene and susceptibility of ovarian hyperstimulation syndrome
Nasrin Ghasemi * 1, Razieh Dehghani Firouzabadi2 , Shahnaz Ahmadi3
1- Recurrent Abortion Research Centre, Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. , nghasemi479@gmail.com
2- Research and Clinical Center for Infertility, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
3- Iran University of Medical Sciences, Tehran, Iran.
Abstract:   (3130 Views)
Background: Ovarian hyperstimulation syndrome (OHSS) is one of the most important complications of assisted reproduction treatment (ART). Many substances are involved in the regulation of the vascular permeability, which have been concerned to cause OHSS. Vascular endothelial growth factor (VEGF) has emerged as one of the main angiogenic factors, which could be responsible for increased vascular permeability.
Objective: This project evaluated potential association between OHSS and VEGF gene -460 C/T and +405 G/C polymorphism.
Materials and Methods: This case-control study was performed at Research and Clinical Center for Infertility, Yazd, Iran for one year. One hundred sixty women enrolled in this study, which were received conventional stimulation. Eighty five of 160 patients were normoresponder (control group) and seventy five were OHSS (case group). After DNA extraction from whole blood by salting-out method, VEGF gene polymorphisms were amplified by PCR-RFLP.
Results: There were no significant difference in the frequency of -460 C/T polymorphism between cases and controls (Chi-square test, p=0.85). The frequency of +405 G/C was significantly higher in the OHSS group (p=0.03, OR=2.44; 95% CI=1.23-4.82).
Conclusion: In women who developed OHSS, VEGF gene polymorphism +405 could be effective. Two of the polymorphisms -460 C/T and +405 G/C were reported to be associated with increased VEGF basal promoter activity. However, only +405 G/C gene polymorphisms was more frequent in cases than controls
Keywords: Ovarian hyperstimulation syndrome, Vascular endothelial growth factor, Gene polymorphism.
Full-Text [PDF 64 kb]   (928 Downloads) |   |   Full-Text (HTML)  (576 Views)  
Type of Study: Original Article |
References
1. McElhinney B, McClure N. Ovarian hyperstimulation syndrome. Baillieres Best Pract Res Clin Obstet Gynaecol 2000; 14: 103-122. [DOI:10.1053/beog.1999.0066]
2. Qazi A, Ahmed AN, Quzi MP, Usman F, Ahmed A. Ischaemic stroke with ovarian hyperstimulation syndrome. J Pak Med Assoc 2008; 58: 411-413.
3. Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome: a review. Hum Reprod Update 2002; 8: 559-577. [DOI:10.1093/humupd/8.6.559]
4. Vlahos NF, Gregoriou O. Prevention and management of ovarian hyperstimulation syndrome. Ann N Y Acad Sci 2006; 1092: 247-264. [DOI:10.1196/annals.1365.021]
5. Ajonuma LC. Is vascular endothelial growth factor (VEGF) the main mediator in ovarian hyperstimulation syndrome (OHSS)? Med Hypothes 2008; 70: 1174-1178. [DOI:10.1016/j.mehy.2007.11.004]
6. Kasum M. New insights in mechanisms for development of ovarian hyperstimulation syndrome. Coll Antropol 2010; 34: 1139-1143.
7. Ozcajir HT, Giray SG, Ozbilgin MK, Uvar Y, Lacin S, Caglar H. Immunohistochemical detection of transforming growth factor alpha, epidermal growth factor, and vascular endothelial growth factor expression in hyperstimulated rat ovary. Acta obstet Gynecol Scand 2005; 84: 887-893.
8. Ozaki NK, Beharry KD, Nishihara KC, Akmal y, Ang JG, Sheikh R, et al. Regulation of retina vascular endothelial growth factor and receptors in rabbits exposed to hyperoxia. Invest Ophtalmol Vis Sci 2002; 43: 1546-1557.
9. Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992; 13: 18-32. [DOI:10.1210/edrv-13-1-18]
10. Ray D, Mishra M, Ralph S, Read I, Davies R, Brenchley P. Association of the VEGF gene with proliferative diabetic rethinopathy but not proteiuria in diabetes. Diabetes 2004; 53: 861-864. [DOI:10.2337/diabetes.53.3.861]
11. Zhai R, Gong MN, Zhou W, Gong MN, Zhou w, Thompson TB, et al. Genotypes and haplotypes of VEGF gene are associated with higher mortality and lower VEGF plasma levels in patients with ARDS. Thorax 2007; 62: 18-22. [DOI:10.1136/thx.2006.069393]
12. Cosin R, Gilabert-Estelles J, Romon LA, Espana F, Gilabert J, Romeu A, Estelles A. Vascular endothelial growth factor polymorphisms (460 C/T, 405 G/C, and 936 C/T) and endometriosis: their influence on vascular endothelial growth factor expression. Fertil Steril 2009; 92: 1214-12220. [DOI:10.1016/j.fertnstert.2008.08.079]
13. Nouri K, Haslinger P, Szabo L, Sator M, Schreiber M, Schneeberger C, Pietrowski D. Polymorphisms of VEGF and VEGF receptors are associated with the occurrence of ovarian hyperstimulation syndrome (OHSS)-a retrospective case-control study. J Ovarian Res 2014; 13: 54. [DOI:10.1186/1757-2215-7-54]
14. Hanevik HI, Hilmarsen HT, Skjelbred CF, Tanbo T, Kahn JA. Increased risk of ovarian hyperstimulation syndrome following controlled ovarian hyperstimulation in patients with vascular endothelial growth factor +405 cc genotype. Gynecol Endocrinol 2012; 28: 845-849. [DOI:10.3109/09513590.2012.683056]
15. Miller SA, Dykes DD, Poleskey HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215. [DOI:10.1093/nar/16.3.1215]
16. Jellad S, Haj Hassine A, Basly M, Mrabet A, Chibani M, Rachdi R. Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome. J Gynecol Obstet Biol Reprod (Paris) 2016; In press.
17. Slattery ML, Lundgreen A, Wolff RK. VEGFA, FLT1, KDR and colorectal cancer: assessment of disease risk, tumor molecular phenotype, and survival. Mol Carcinog 2014; 53 (Suppl.): 140-150. [DOI:10.1002/mc.22058]
18. Scartozzi M, Bianconi M, Faloppi L, Loretelli C, Bittoni A, Del Prete M, et al. VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib. Br J Cancer 2013; 108: 1126-1132. [DOI:10.1038/bjc.2012.501]
19. Shibuya M. Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. J Biochem 2013; 153: 13-19. [DOI:10.1093/jb/mvs136]
20. Honarvar N, Sheikhha MH, Farashahi Yazd E, Pashaiefar H, Mohtaram S, Sazegari A, Feizollahi Z, Ghasemi N. KDR gene polymorphisms and idiopathic recurrent spontaneous abortion. J Matern Fetal Neonatal Med 2016; 29: 3737-3740. [DOI:10.3109/14767058.2016.1142966]
21. Su MT, Lin SH, Lee IW, Chen YC, Kuo PL. Association of polymorphisms/haplotypes of the genes encoding vascular endothelial growth factor and its KDR receptor with recurrent pregnancy loss. Hum Reprod 2011; 26: 758-764. [DOI:10.1093/humrep/deq401]
22. Otani N, Minami S, Yamoto M, Shikone T, Otani H, Nishiyama R, et al. The vascular endothelial growth factor / fms-like tyrosine kinase system in human ovary during menstrual cycle and early pregnancy. J Clin Endocrinol Metab 1999; 84: 3845-3851. [DOI:10.1210/jcem.84.10.6025]
23. Watkins RH, D'Angio CT, Ryan RM, Patel A, Maniscalco WM, et al. Differential expression of VEGF mRNA splice variants in newborn and adult hyperoxic lung injury. Am J Physiol 1999; 276: 858-867. [DOI:10.1152/ajplung.1999.276.5.L858]
24. Coulam CB, Jeyendran RS. Vascular endothelial growth factor gene polymorphism and recurrent pregnancy loss. Am J Reprod Immunol 2008; 59: 301-305. [DOI:10.1111/j.1600-0897.2007.00515.x]
25. Senger DR, Perruzzi CA, Feder J, Dvorak HF. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 1986; 46: 5629-5632.
26. Davis JS, Rueda BR, Spanel-Borowski K.Microvascular endothelial cells of the corpus luteum. Reprod Biol Endocrinol 2003; 1: 89. [DOI:10.1186/1477-7827-1-89]
27. Summers AM, Coupes BM, Brenan MF, Ralph SA, Short CD, Brenchley PE. VEGF 460 genotype plays an important role in progression to chronic kidney disease stage 5. Nephrol Dial Trasplant 2005; 20: 2427-2432. [DOI:10.1093/ndt/gfi029]
28. Neulen J, Raczek S, Pogorzelski M, Grunwald K, Yeo Tk, Dvorak HF, et al. Secretion of vascular endothelial growth facror/ vascular permeability factor from human luteinized granulose cells in human chorionic gonadotropin dependent. Mol Hum Reprod 1998; 4: 203-206. [DOI:10.1093/molehr/4.3.203]
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Designed & Developed by : Yektaweb